246 related articles for article (PubMed ID: 33863349)
1. Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis.
Klotsche J; Klein A; Niewerth M; Hoff P; Windschall D; Foeldvari I; Haas JP; Horneff G; Minden K
Arthritis Res Ther; 2021 Apr; 23(1):118. PubMed ID: 33863349
[TBL] [Abstract][Full Text] [Related]
2. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
4. Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial.
Alexeeva E; Horneff G; Dvoryakovskaya T; Denisova R; Nikishina I; Zholobova E; Malievskiy V; Santalova G; Stadler E; Balykova L; Spivakovskiy Y; Kriulin I; Alshevskaya A; Moskalev A
Pediatr Rheumatol Online J; 2021 Jan; 19(1):5. PubMed ID: 33407590
[TBL] [Abstract][Full Text] [Related]
5. Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.
Klotsche J; Minden K; Niewerth M; Horneff G
Ann Rheum Dis; 2018 Jul; 77(7):996-1002. PubMed ID: 29453217
[TBL] [Abstract][Full Text] [Related]
6. Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis.
Yue X; Huang B; Hincapie AL; Wigle PR; Qiu T; Li Y; Morgan EM; Guo JJ
Paediatr Drugs; 2021 Mar; 23(2):171-182. PubMed ID: 33651370
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors.
Gieling J; van den Bemt B; Hoppenreijs E; Schatorjé E
Pediatr Rheumatol Online J; 2022 Dec; 20(1):109. PubMed ID: 36471348
[TBL] [Abstract][Full Text] [Related]
8. Outcome of adult patients with JIA treated with the biosimilar Benepali
Vollbach K; Tenbrock K; Wagner N; Horneff G; Klein A; Foeldvari I; Haas JP; Aries P; Gauler G; Striesow F; Hoff P; Scholz C; Tatsis S; Seipelt E; Klotsche J; Minden K
Arthritis Res Ther; 2022 Dec; 24(1):271. PubMed ID: 36514116
[TBL] [Abstract][Full Text] [Related]
9. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of concomitant therapy in children with juvenile idiopathic arthritis treated with etanercept and methotrexate.
Alexeeva E; Dvoryakovskaya T; Denisova R; Sleptsova T; Isaeva K; Chomahidze A; Fetisova A; Mamutova A; Alshevskaya A; Gladkikh V; Moskalev A
Pediatr Neonatol; 2019 Oct; 60(5):549-555. PubMed ID: 30885783
[TBL] [Abstract][Full Text] [Related]
12. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.
Horneff G; Klein A; Klotsche J; Minden K; Huppertz HI; Weller-Heinemann F; Kuemmerle-Deschner J; Haas JP; Hospach A
Arthritis Res Ther; 2016 Nov; 18(1):272. PubMed ID: 27881144
[TBL] [Abstract][Full Text] [Related]
13. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
Windschall D; Horneff G
Clin Rheumatol; 2016 Dec; 35(12):2925-2931. PubMed ID: 27709443
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Flare Following Etanercept Withdrawal in Patients with Rheumatoid Factor-negative Juvenile Idiopathic Arthritis Who Reached Remission while Taking Medication.
Aquilani A; Marafon DP; Marasco E; Nicolai R; Messia V; Perfetti F; Magni-Manzoni S; De Benedetti F
J Rheumatol; 2018 Jul; 45(7):956-961. PubMed ID: 29717035
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years.
Windschall D; Müller T; Becker I; Horneff G
Rheumatol Int; 2015 Apr; 35(4):613-8. PubMed ID: 25208527
[TBL] [Abstract][Full Text] [Related]
17. Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial.
Hissink Muller P; Brinkman DMC; Schonenberg-Meinema D; van den Bosch WB; Koopman-Keemink Y; Brederije ICJ; Bekkering PW; Kuijpers TW; Van Rossum M; van Suijlekom-Smit LWA; van den Berg JM; Boehringer S; Allaart CF; Ten Cate R
Ann Rheum Dis; 2019 Jan; 78(1):51-59. PubMed ID: 30309970
[TBL] [Abstract][Full Text] [Related]
18. When should the use of biological agents be considered in persistent oligoarticular juvenile idiopathic arthritis patients?
Polat MC; Çelikel E; Tekin ZE; Kurt T; Kaplan MM; Güngörer V; Tekgöz N; Sezer M; Karagöl C; Coşkun S; Öner N; Sezer S; Acar BÇ
Eur J Pediatr; 2024 Jun; 183(6):2725-2731. PubMed ID: 38554171
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry.
Armaroli G; Klein A; Ganser G; Ruehlmann MJ; Dressler F; Hospach A; Minden K; Trauzeddel R; Foeldvari I; Kuemmerle-Deschner J; Weller-Heinemann F; Urban A; Horneff G
Arthritis Res Ther; 2020 Oct; 22(1):258. PubMed ID: 33121528
[TBL] [Abstract][Full Text] [Related]
20. Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept.
Verazza S; Davì S; Consolaro A; Bovis F; Insalaco A; Magni-Manzoni S; Nicolai R; Marafon DP; De Benedetti F; Gerloni V; Pontikaki I; Rovelli F; Cimaz R; Marino A; Zulian F; Martini G; Pastore S; Sandrin C; Corona F; Torcoletti M; Conti G; Fede C; Barone P; Cattalini M; Cortis E; Breda L; Olivieri AN; Civino A; Podda R; Rigante D; La Torre F; D'Angelo G; Jorini M; Gallizzi R; Maggio MC; Consolini R; De Fanti A; Muratore V; Alpigiani MG; Ruperto N; Martini A; Ravelli A;
Pediatr Rheumatol Online J; 2016 Dec; 14(1):68. PubMed ID: 27993144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
